sdAb-based TRNT of Multiple Myeloma: a Feasibility Study (MUM)

Universitair Ziekenhuis Brussel

Status: Completed

Conditions: Multiple Myeloma

Treatments: Other: Blood sampling and bone marrow analysis

Study type: Interventional

Funder types: Other

Identifiers

NCT03956615

UZBRU_MUM

Details and patient eligibility

About

This study aims to show that antiidiotypic sdAb are a new, sensitive, specific and non-invasive tool for imaging and therapeutic purposes and provides a rationale for their clinical evaluation as a personalized treatment option for MM patients expressing surface paraprotein.

Enrollment: 10 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Patients will only be included in the study if they meet all of the following criteria:

• Patients who have given informed consent
• Patients at least 18 years old
• Patients scheduled to undergo bone marrow sampling in clinical routine because of a clinically suspected or pathologically confirmed multiple myeloma.

Exclusion criteria

Patients will not be included in the study if one of the following criteria applies:

• Patients who cannot communicate reliably with the investigator
• Patients who are unlikely to cooperate with the requirements of the study
• Patients at increased risk of death from a pre-existing concurrent illness
• Patients who participated already in part I of this study

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

10 participants in 1 patient group

Clinically Suspected or Pathologically Confirmed Multiple Myeloma.

Other group

Description:

Patients with a clinically suspected or pathologically confirmed multiple myeloma.

Treatment:

Other: Blood sampling and bone marrow analysis